Trends in Population-Level Lung Cancer Mortality

Non–small-cell lung cancer incidence-based mortality declined annually from 2001 through 2016, following advances in targeted therapies.

Population mortality trends according to cancer subtypes are lacking. To evaluate recent trends in population-level U.S. mortality attributable to non–small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), investigators linked mortality records from the National Center for Health Statistics with incident histologic tumor types reported to Surveillance, Epidemiology, and End Results (SEER) registries from 2001 through 2016. The researchers calculated population-level, incidence-based mortality by dividing the number of cancer-specific deaths among persons with a particular cancer diagnosis by the general population at risk at the time of death in the SEER areas.

Results were as follows:

NSCLC incidence in men decreased annually by 1…

Reviewing Author

Anne S. Tsao, MD

Disclosures

Consultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology

RoyaltiesUpToDate

Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb

Anne S. Tsao, MD

Disclosures

RoyaltiesUpToDate

Trends in Population-Level Lung Cancer Mortality

Topics

Reviewing Author